TY - JOUR
T1 - Influence of population diversity on neurovirulence potential of plaque purified L-Zagreb variants
AU - Ivancic-Jelecki, Jelena
AU - Forcic, Dubravko
AU - Jagusic, Maja
AU - Kosutic-Gulija, Tanja
AU - Mazuran, Renata
AU - Lang Balija, Maja
AU - Isakov, Ofer
AU - Shomron, Noam
N1 - Publisher Copyright:
© 2016 Elsevier Ltd.
PY - 2016/4/29
Y1 - 2016/4/29
N2 - Background: Despite continuing research efforts, determinants of mumps virus virulence are still largely unknown. One of consequences of this is difficulty in striking a balance between efficacy and safety of live attenuated mumps vaccines. Among mumps vaccine strains associated with occurrence of postvaccinal aseptic meningitis is L-Zagreb, developed by further attenuation of vaccine strain L-3. Starting from an archived L-Zagreb sample with suboptimal neuroattenuation score, we isolated different viral variants and compared their genetic and phenotypic properties, in investigation of neurovirulence markers. Methods: Six different L-Zagreb variants were isolated by plaque purification. Their neurovirulent status was determined by rat-based neurovirulence test; population structure was determined by deep sequencing. Results: We isolated one well neuroattenuated viral variant, two marginally neuroattenuated, and three insufficiently neuroattenuated. No genetic markers of neurovirulence could be identified. None of variants had detectable amounts of defective interfering particles. Two characteristics set insufficiently neuroattenuated variants apart from less-neurovirulent ones: elevated variability level in regions 1293-3314, 5363-7773 and 9382-11657, and/or elevated number of mutations present in frequencies ≥1%. The most neurovirulent variants possessed both of these features. Conclusions: Distinctive heterogeneity profiles were obtained for insufficiently neuroattenuated L-Zagreb variants. No markers that would discriminate between marginally and well neuroattenuated variants were identified. The findings of this study may serve as a guideline during development of an improved L3/L-Zagreb vaccine strain.
AB - Background: Despite continuing research efforts, determinants of mumps virus virulence are still largely unknown. One of consequences of this is difficulty in striking a balance between efficacy and safety of live attenuated mumps vaccines. Among mumps vaccine strains associated with occurrence of postvaccinal aseptic meningitis is L-Zagreb, developed by further attenuation of vaccine strain L-3. Starting from an archived L-Zagreb sample with suboptimal neuroattenuation score, we isolated different viral variants and compared their genetic and phenotypic properties, in investigation of neurovirulence markers. Methods: Six different L-Zagreb variants were isolated by plaque purification. Their neurovirulent status was determined by rat-based neurovirulence test; population structure was determined by deep sequencing. Results: We isolated one well neuroattenuated viral variant, two marginally neuroattenuated, and three insufficiently neuroattenuated. No genetic markers of neurovirulence could be identified. None of variants had detectable amounts of defective interfering particles. Two characteristics set insufficiently neuroattenuated variants apart from less-neurovirulent ones: elevated variability level in regions 1293-3314, 5363-7773 and 9382-11657, and/or elevated number of mutations present in frequencies ≥1%. The most neurovirulent variants possessed both of these features. Conclusions: Distinctive heterogeneity profiles were obtained for insufficiently neuroattenuated L-Zagreb variants. No markers that would discriminate between marginally and well neuroattenuated variants were identified. The findings of this study may serve as a guideline during development of an improved L3/L-Zagreb vaccine strain.
KW - L-Zagreb
KW - Mumps
KW - Mumps vaccine
KW - Rat-based neurovirulence test
KW - Virus population diversity
KW - Virus variants
UR - http://www.scopus.com/inward/record.url?scp=84962034220&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2016.03.033
DO - 10.1016/j.vaccine.2016.03.033
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84962034220
SN - 0264-410X
VL - 34
SP - 2383
EP - 2389
JO - Vaccine
JF - Vaccine
IS - 20
ER -